AbbVie Inc.
AbbVie Announces First-Quarter 2024 Results and Leadership Transition
Summary
AbbVie Inc. reported its first-quarter 2024 financial results, showing a significant increase in GAAP diluted EPS to $0.77, up from $0.13 in the prior year, while adjusted diluted EPS slightly decreased to $2.31. The company's net revenues grew by 0.7% to $12.310 billion. AbbVie also announced a leadership transition with Robert A. Michael set to become the new CEO, succeeding Richard A. Gonzalez who will retire and become executive chairman. The company completed the acquisition of ImmunoGen and received FDA approval for Elahere, its flagship cancer therapy. AbbVie raised its full-year 2024 adjusted diluted EPS guidance to $11.13 - $11.33.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement